ErbB4 targeting approaches for prostate cancer treatment.
Wheeler
D L
DL
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Rangnekar
Vivek M
VM
Schwarze
S R
SR
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D003131:Combined Modality Therapy; D004354:Drug Screening Assays, Antitumor; D066246:ErbB Receptors / Q000737:chemistry* / Q000276:immunology; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008954:Models, Biological; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000628:therapy*; D066247:Receptor, ErbB-4
D000911:Antibodies, Monoclonal; C587689:ERBB4 protein, human; D066246:ErbB Receptors; C587690:Erbb4 protein, mouse; D066247:Receptor, ErbB-4